Cargando…
Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway
This study explored the mechanism by which metformin (Met) inhibits osteoclast activation and determined its effects on osteoarthritis (OA) mice. Bone marrow-derived macrophages were isolated. Osteoclastogenesis was detected using tartrate-resistant acid phosphatase (TRAP) staining. Cell proliferati...
Autores principales: | Guo, Haohui, Ding, Dong, Wang, Limei, Yan, Jiangbo, Ma, Long, Jin, Qunhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675877/ https://www.ncbi.nlm.nih.gov/pubmed/34914744 http://dx.doi.org/10.1371/journal.pone.0261127 |
Ejemplares similares
-
Osteoclasts secrete leukemia inhibitory factor to promote abnormal bone remodeling of subchondral bone in osteoarthritis
por: Zhao, Xin, et al.
Publicado: (2022) -
Metformin alleviates osteoarthritis in mice by inhibiting chondrocyte ferroptosis and improving subchondral osteosclerosis and angiogenesis
por: Yan, Jiangbo, et al.
Publicado: (2022) -
Dihydroartemisinin attenuates osteoarthritis by inhibiting abnormal bone remodeling and angiogenesis in subchondral bone
por: Ma, Long, et al.
Publicado: (2021) -
Sclerostin expression in the subchondral bone of patients with knee osteoarthritis
por: Wu, Long, et al.
Publicado: (2016) -
Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF-κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis
por: Ding, Dong, et al.
Publicado: (2022)